Skip to main content
. 2017 Jun 7;13(6):e1006347. doi: 10.1371/journal.ppat.1006347

Fig 3. ERRα negatively regulates IFN-I production both in vitro and in vivo.

Fig 3

(A) ELISA analysis of IFN-β secretion in WT and ERRα-KO BMDMs transfected with Lipofectamine, 5’-ppp dsRNA (0.1 g/ml), poly (I:C) (0.1 g /ml), poly(dA:dT) (0.1 g /ml) and c-di-GMP (10 g /ml) or incubated with the Medium control (Med), HMW poly(I:C) (0.5 g/ml), LPS (0.1 g /ml) or flagellin (1 g /ml) for 12 h. (B) qRT-PCR analysis of IFN-β mRNA expression in WT and ERRα-KO BMDMs treated as shown in Fig 3A. (C-D) ELISA analysis of IFN-β (C) and qRT-PCR analysis of IFN-β mRNA (D) expression in WT and ERRα-KO BMDMs infected with VSV for the indicated hours. (E) IFN-β promoter luciferase activity assays in shCtrl or shERRα-2 293T cell lines infected with VSV (MOI = 1.0) for 12 h. (F) qRT-PCR analysis of IFN-β mRNA expression in lung, liver or spleen isolated from WT and ERRα-KO mice given tail vein injections of VSV for 24 h (n = 6 per group). (G) ELISA analysis of IFN-β protein in sera from WT and ERRα-KO mice given tail vein injections of VSV for 24 h (n = 6 per group). (H) Pathology of WT and ERRα-KO mice in response to VSV. Scale bar, 100 mm. HE staining of lung sections. Loading controls were shown in the lower panel of some Figures. Cell-based studies were performed independently at least three times with comparable results. The data are presented as the means ± SEM.